Welcome


SURVIVE CANCER (ORTHOMOLECULAR ONCOLOGY)
Registered Charity No. 1078066

A Cancer Charity which promotes and researches orthomolecular medicine in the treatment of cancer.

Patrons

  • HRH Princess Michael of Kent
  • The Earl Baldwin of Bewdley
    (Co-Chairman of the Parliamentary Commitee for Alternative and Complementary Medicine)
  • Dr Damien Downing, MBBS, (Editor of The Journal of Nutritional and Environmental Medicine)
  • Mr Peter J Gravett, MB, MRCS, FRCPath.
  • Dr P J Kingsley, MB, BS, MRCS, LRCP, FAAEM, DA, D.Obst. RCOG

Scientific Advisor

  • Professor Mauro Perretti, PhD, FBPharmacolS, Deputy Director William Harvey Research Institute

NEW THEORY OF THE CAUSE OF PATHOLOGICAL INFLAMMATION:

DR CARMEN WHEATLEY'S NEW PAPER is now publlshed online at:
  Hypotheses in the Life Sciences.

http://www.hy-ls.org/index.php/hyls

The Very Large Gorilla Sitting in the Room?
Adenosylcobalamin is the Missing Link: its Radical and Tetrahydrobiopterin are the Principal in vivo Catalysts for Mammalian Nitric Oxide Synthases.

Carmen Wheatley

LINK TO ABSTRACT: ABSTRACT.pdf

 

WHAT'S NEW IN CANCER TREATMENTS?

EPA derivative cures leukemia in mice

Sandeep Prabhu and colleagues at Pennsylvania State University report in the December 22, 2011 issue of the journal Blood that a compound derived from eicosapentaenoic acid (EPA), an omega 3 fatty acid that occurs in high amounts in fish, cured chronic myelogenous leukemia (CML) in two mouse models of the disease.

In recent research, cyclooxygenase-derived cyclopentenone prostaglandins (CyPGs) were identified as possible agents to target cancer stem cells. Currently available treatments for leukemia and other cancers fail to destroy stem cells, which results in relapses of the disease. "The patients must take the drugs continuously," noted study coauthor Robert F. Paulson, who is an associate professor of veterinary and biomedical sciences at Penn State. "If they stop, the disease relapses because the leukemia stem cells are resistant to the drugs."

For the current experiments, the researchers administered a CyPG compound known as delta-12-protaglandin J3 (D12-PGJ3, derived from EPA) to leukemic mice for one week. Animals that received the compound had normal spleens and blood counts, and increased survival without relapse after being treated. "This treatment completely eradicated leukemia stem cells in vivo, as demonstrated by the inability of donor cells from treated mice to cause leukemia in secondary transplantations," the authors write.

"Research in the past on fatty acids has shown the health benefits of fatty acids on cardiovascular system and brain development, particularly in infants, but we have shown that some metabolites of omega 3 have the ability to selectively kill the leukemia-causing stem cells in mice," stated Dr Prabhu, who is an associate professor of immunology and molecular toxicology at Penn State's Department of Veterinary and Medical Sciences. "The important thing is that the mice were completely cured of leukemia with no relapse."

FOXFIRE - A trial of chemotherapy with or without radioembolisation for bowel cancer that has spread to the liver

This trial is looking at a treatment called radioembolisation for bowel cancer that has spread to the liver and cannot be removed with surgery.

If bowel cancer spreads, it often goes to the liver. Sometimes it is possible to remove bowel cancer that has spread to the liver with surgery. If it cannot be completely removed with surgery, chemotherapy can shrink or control the cancer, but it does not cure it.

Doctors are looking for new treatments that will help to control bowel cancer that has spread to the liver. In this trial, they are looking at a treatment called radioembolisation. It uses very small radioactive beads called microspheres.

The doctor injects the microspheres directly into the blood vessels near the cancer in the liver. The beads give off radiation for a few days. The radiation damages the cancer cells and the cancer’s blood supply. As the microspheres only give off radiation to a small area, they cause little damage to the surrounding healthy tissue. This treatment is also called Selective Internal Radiation Therapy (SIRT).

The aims of the trial are to

  • See if the combination of radioembolisation and chemotherapy works better than chemotherapy alone for bowel cancer that has spread to the liver
  • Learn more about the side effects of radioembolisation when it is combined with chemotherapy

See Daily Telegraph article about someone who has already benefited from the trial: http://www.telegraph.co.uk/health/8733645/Miracle-technique-cures-grandf...

A New Vaccine for Ovarian and Breast Cancer shows promise

A new vaccine that targets ovarian and breast cancer has shown promise in early studies, giving scientists hope they may be closer to stopping the deadly diseases.
Known as PANVAC, the vaccine triggers the immune system to attack tumor cells.
"With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients," lead scientist Dr. James Gulley, director and deputy chief of the clinical trials group at the laboratory of tumor immunology and biology at the National Cancer Institute, said in a written statement.

See the full text of the article at:
http://www.cbsnews.com/8301-504763_162-57321522-10391704/vaccine-for-ova...

And the paper on which the article is based:
http://clincancerres.aacrjournals.org/content/early/2011/11/04/1078-0432...

NEW books:

Customized Cancer Treatment, Ralph W Moss, (Equinox 2010)

Customized Cancer Treatment is the first book for the layperson on chemosensitivity testing. This is a laboratory procedure by which patients and their doctors can discover which drugs are mostly like to work for them and which to avoid. Chemosensitivity testing is very effective at finding the best drugs for each individual. It is a form of personalized treatment. According to Dr. Robert Nagourney, No cancer patient should begin treatment without first reading this book.

AttachmentSize
ABSTRACT.pdf313.99 KB